
Navigating Treatment in ATTR-CM's New Era, with Ahmad Masri, MD, MS
The approvals of acoramidis (Attruby) and vutrisiran (Amvuttra) represent a step forward into a new era of management for transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Awarded in November 2024 and March 2025, respectively, the agents …